According to a report from Europol’s Intellectual Property Crime Threat Assessment 2019, “Counterfeit pharmaceuticals pose a growing threat to the EU, affecting a large number of Member States. A wide and increasingly diverse range of medicines is targeted by counterfeiters.”
The Europol ICP Threat Assessment reports that there has been an increase in seizures of counterfeit drugs used in the treatment of serious illnesses, as well as a growing number of counterfeit drug incidents affecting the legal drug supply chain.
In a report published by the House of Commons, experts in the field of prescription medication described a dire situation for medicine safety in the United Kingdom (UK) if a “no-deal” departure from the European Union (EU) happens. The report noted, “Witnesses told us that, without provisions with the EU to continue to exchange data, the UK would be shut out of critical EU data exchanges on pharmacovigilance, falsified medicines and clinical trials.”[...]